Navigation Links
Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
Date:6/24/2009

MORRISTOWN, N.J., June 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women seventeen years and younger. Levonorgestrel is the generic equivalent to Duramed Pharmaceuticals' PLAN B(R), which is indicated for the prevention of pregnancy following unprotected intercourse or contraceptive failure. This product is approved for prescription use only. The Company intends to market the product under the trade name Next Choice(TM) and plans to launch the product shortly. For the 12-months ending March 2009, PLAN B(R) had total U.S. sales of approximately $123 million, of which approximately ten percent are attributable to prescription sales, according to IMS sales data. PLAN B(R) over-the-counter (O.T.C.) new product exclusivity expires on August 24, 2009.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

PLAN B(R) is a registered trademark of Women's Capital Corporation, a subsidiary of Duramed Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson to Acquire Arrow Group
2. Watson Files FDA Application for Generic Mucinex(R) D
3. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
4. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
5. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
6. Watson Files FDA Applications for Generic Mucinex(R)
7. Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting
8. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
9. Mark G. Watson Named Executive Director of Radiological Society of North America
10. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
11. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Western University of Health Sciences and ... developmentally disabled in the Coachella Valley. , The two entities, through an expanded ... Highway 111, Suite 100-B, in Rancho Mirage, California. The new site has 11 ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... (VRI) within Healthcare, recently partnered with Heart City Health Center to ... nearly 23 years, Heart City Health Center has provided the Elkhart community with ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Peyman Ghasri, skin doctor ... variety of comprehensive procedures for facial enhancement. The treatments now available at Castle ... and nasal reshaping. , As a result, patients can improve virtually every ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... San Diego, will bring together more than 200 of the country’s top healthcare ... the future. , “The true benefit of the Forum is the provider-centric perspective, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... PRINCETON, New Jersey and OR AKIVA, ... Regentis Biomaterials Ltd., a leader ... of its Series D investment round on February 5, ... Haisco Pharmaceutical Group ("Haisco"), a leading Chinese pharmaceutical ... Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ALSP, ... Hack , MD as Consultant for Medical Affairs in preparation ... Michael Pierschbacher , PhD, CEO, stated, "We are ... team. We look forward to working with an individual of ... (TBI). We look forward to drawing deeply on his broad ...
(Date:2/10/2016)... , February 10, 2016 ... market research report "Pharmaceutical Packaging Equipment Market by Package ... & Serialization), by Product Type (Tablet, Powder, Cream, Syrup, ... by MarketsandMarkets, studies the global market during the forecast period ... grow at a CAGR of 6.9% during the forecast ...
Breaking Medicine Technology: